These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 15024183)

  • 1. Immune response against gene therapy vectors: influence of synovial fluid on adeno-associated virus mediated gene transfer to chondrocytes.
    Cottard V; Valvason C; Falgarone G; Lutomski D; Boissier MC; Bessis N
    J Clin Immunol; 2004 Mar; 24(2):162-9. PubMed ID: 15024183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synoviocyte infection with adeno-associated virus (AAV) is neutralized by human synovial fluid from arthritis patients and depends on AAV serotype.
    Boissier MC; Lemeiter D; Clavel C; Valvason C; Laroche L; Begue T; Bessis N
    Hum Gene Ther; 2007 Jun; 18(6):525-35. PubMed ID: 17532727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue.
    Mingozzi F; Chen Y; Edmonson SC; Zhou S; Thurlings RM; Tak PP; High KA; Vervoordeldonk MJ
    Gene Ther; 2013 Apr; 20(4):417-24. PubMed ID: 22786533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyaluronic acid synthase-2 gene transfer into the joints of Beagles by use of recombinant adeno-associated viral vectors.
    Kyostio-Moore S; Berthelette P; Cornell CS; Nambiar B; Figueiredo MD
    Am J Vet Res; 2018 May; 79(5):505-517. PubMed ID: 29688780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capsid-specific removal of circulating antibodies to adeno-associated virus vectors.
    Bertin B; Veron P; Leborgne C; Deschamps JY; Moullec S; Fromes Y; Collaud F; Boutin S; Latournerie V; van Wittenberghe L; Delache B; Le Grand R; Dereuddre-Bosquet N; Benveniste O; Moullier P; Masurier C; Merten O; Mingozzi F
    Sci Rep; 2020 Jan; 10(1):864. PubMed ID: 31965041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of adeno-associated virus-specific immunoglobulin G in human amniotic fluid on gene transfer.
    Boyle MP; Enke RA; Mogayzel PJ; Guggino WB; Martin DB; Agarwal S; Zeitlin PL
    Hum Gene Ther; 2003 Mar; 14(4):365-73. PubMed ID: 12659677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.
    Boutin S; Monteilhet V; Veron P; Leborgne C; Benveniste O; Montus MF; Masurier C
    Hum Gene Ther; 2010 Jun; 21(6):704-12. PubMed ID: 20095819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A convenient enzyme-linked immunosorbent assay for rapid screening of anti-adeno-associated virus neutralizing antibodies.
    Ito T; Yamamoto S; Hayashi T; Kodera M; Mizukami H; Ozawa K; Muramatsu S
    Ann Clin Biochem; 2009 Nov; 46(Pt 6):508-10. PubMed ID: 19729501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement is an essential component of the immune response to adeno-associated virus vectors.
    Zaiss AK; Cotter MJ; White LR; Clark SA; Wong NC; Holers VM; Bartlett JS; Muruve DA
    J Virol; 2008 Mar; 82(6):2727-40. PubMed ID: 18199646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of blood and synovial fluid immune complexes of patients with rheumatoid arthritis on production of nitric oxide and growth and viability of chondrocytes.
    Verbruggen A; De Clerck LS; Bridts CH; Breedveld FC; Stevens WJ
    J Rheumatol; 2000 Jan; 27(1):35-40. PubMed ID: 10648015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions.
    Masat E; Pavani G; Mingozzi F
    Discov Med; 2013 Jun; 15(85):379-89. PubMed ID: 23819952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing Antibodies Against Adeno-Associated Virus (AAV): Measurement and Influence on Retinal Gene Delivery.
    Desrosiers M; Dalkara D
    Methods Mol Biol; 2018; 1715():225-238. PubMed ID: 29188517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adeno-associated virus vector-mediated anti-angiogenic gene therapy for collagen-induced arthritis in mice.
    Takahashi H; Kato K; Miyake K; Hirai Y; Yoshino S; Shimada T
    Clin Exp Rheumatol; 2005; 23(4):455-61. PubMed ID: 16095112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.
    Janelidze S; Nordström U; Kügler S; Brundin P
    J Gene Med; 2014; 16(9-10):300-8. PubMed ID: 25303717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy methods in bone and joint disorders. Evaluation of the adeno-associated virus vector in experimental models of articular cartilage disorders, periprosthetic osteolysis and bone healing.
    Ulrich-Vinther M
    Acta Orthop Suppl; 2007 Apr; 78(325):1-64. PubMed ID: 17427340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing antibodies against adeno-associated viruses in inflammatory bowel disease patients: implications for gene therapy.
    van der Marel S; Comijn EM; Verspaget HW; van Deventer S; van den Brink GR; Petry H; Hommes DW; Ferreira V
    Inflamm Bowel Dis; 2011 Dec; 17(12):2436-42. PubMed ID: 21370319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors.
    Shi W; Arnold GS; Bartlett JS
    Hum Gene Ther; 2001 Sep; 12(14):1697-711. PubMed ID: 11560765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure.
    Moskalenko M; Chen L; van Roey M; Donahue BA; Snyder RO; McArthur JG; Patel SD
    J Virol; 2000 Feb; 74(4):1761-6. PubMed ID: 10644347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.
    Leborgne C; Latournerie V; Boutin S; Desgue D; Quéré A; Pignot E; Collaud F; Charles S; Simon Sola M; Masat E; Jouen F; Boyer O; Masurier C; Mingozzi F; Veron P
    Cell Immunol; 2019 Aug; 342():103780. PubMed ID: 29571923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.
    Hareendran S; Balakrishnan B; Sen D; Kumar S; Srivastava A; Jayandharan GR
    Rev Med Virol; 2013 Nov; 23(6):399-413. PubMed ID: 24023004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.